OR WAIT null SECS
Forecast is for 3-6% CAGR through 2022
IQVIA has published is annual data on global drug spending trends this year as part of a larger report, “2018 and Beyond: Outlook and Turning Points,” highlighting evolving trends in healthcare and drug utilization practices—which we’ll get to in a moment. Staying with the macro spending trends, the findings include:
Dominant trends for how drugs are launched, managed and reimbursed include:
However, IQVIA also downplays the impact of outcomes-based contracting, saying that “the administrative burden on all parties will escalate and become prohibitive unless the outcomes are designed to be measurable.”
The full report, from the IQVIA Institute for Human Data Science, is available here.